Search Results - "Cutler, N. R."

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit by GIACOBINI, E, SPIEGEL, R, ENZ, A, VEROFF, A. E, CUTLER, N. R

“…Cholinesterase (ChE) inhibition represents the most efficacious treatment approach for Alzheimer's disease (AD) to date. This multiple-dose study has examined…”
Get full text

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach by Kittelson, J. M., Spyropoulos, A. C., Halperin, J. L., Kessler, C. M., Schulman, S., Steg, G., Turpie, A. G. G., Cutler, N. R., Hiatt, W. R., Goldenberg, N. A.

“…Summary Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically…”
Get full text

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? by SPYROPOULOS, A. C., GOLDENBERG, N. A., KESSLER, C. M., KITTELSON, J., SCHULMAN, S., TURPIE, A. G. G., CUTLER, N. R., HIATT, W. R., HALPERIN, J. L.

“…Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AGG, Cutler NR, Hiatt WR, Halperin JL. Comparative effectiveness and safety of the…”
Get full text

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial by March, John S, Biederman, Joseph, Wolkow, Robert, Safferman, Allan, Mardekian, Jack, Cook, Edwin H, Cutler, Neal R, Dominguez, Roberto, Ferguson, James, Muller, Betty, Riesenberg, Robert, Rosenthal, Murray, Sallee, Floyd R, Wagner, Karen D

“…CONTEXT.— The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this…”
Get full text

Review of the acetylcholinesterase inhibitor galanthamine by Sramek, J J, Frackiewicz, E J, Cutler, N R

“…Galanthamine (or galantamine, Reminyl) is a tertiary alkaloid acetylcholinesterase inhibitor (AChEI) which has been approved in several countries for the…”
Get more information

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease by Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., Zolnouni, P.

“…Introduction ‐ This study evaluates the activity of SDZ ENA 713, a centrally‐selective acetylcholinesterase (AChE) inhibitor, in the cerebral spinal fluid…”
Get full text

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease by Krall, WJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To provide a review of acetylcholinesterase inhibitors (AChEIs) tested as therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE…”
Get full text

Recent developments in the drug treatment of Alzheimer's disease by SRAMEK, J. J, CUTLER, N. R

“…Alzheimer's disease (AD) is a chronic neurodegenerative disorder with an impact on public health which continues to increase with the increasing longevity of…”
Get full text

Cholinergic Rebound and Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal by Shiovitz, Thomas M., Welke, Timothy L., Tigel, Phillip D., Anand, Ravi, Hartman, Richard D., Sramek, John J., Kurtz, Neil M., Cutler, Neal R.

“…Following the conduct of a 28-day inpatient bioequivalence study of clozapine in schizophrenia patients, withdrawal effects after abrupt discontinuation from…”
Get full text

Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients by Cutler, N R

“…In clinical trials of dopamine-blocking antipsychotics, significant adverse events may occur in healthy volunteers at dose levels that are well tolerated by…”
Get full text

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine by Gomez-Mancilla, B, Cutler, N R, Leibowitz, M T, Spierings, E L, Klapper, J A, Diamond, S, Goldstein, J, Smith, T, Couch, J R, Fleishaker, J, Azie, N, Blunt, D E

“…In this randomized, double-blind, placebo-controlled, parallel-group study, patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 (n =…”
Get more information

Pramipexole in patients with early Parkinson's disease by Hubble, J P, Koller, W C, Cutler, N R, Sramek, J J, Friedman, J, Goetz, C, Ranhosky, A, Korts, D, Elvin, A

“…We evaluated the efficacy, safety, tolerability, and pharmacokinetics of pramipexole, a novel dopamine D2 receptor agonist, in early Parkinson's disease (PD)…”
Get more information

Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease by Gobburu, J.V.S., Tammara, V, Lesko, L, Jhee, S. S., Sramek, J. J., Cutler, N. R., Yuan, Ruihua

“…Rivastigmine is a cholinersterase inhibitor approved recently for the treatment of Alzheimer's disease (AD). The objective of this study is to characterize the…”
Get full text

Positron emission tomography in Alzheimer's disease by DUARA, R, GRADY, C, HAXBY, J, SUNDARAM, M, CUTLER, N. R, HESTON, L, MOORE, A, SCHLAGETER, N, LARSON, S, RAPOPORT, S. I

“…Twenty-one patients with a clinical diagnosis of dementia of the Alzheimer's type (DAT) and 29 healthy, age-matched controls were studied using positron…”
Get full text

Gender differences in depression and antidepressant pharmacokinetics and adverse events by Frackiewicz, EJ, Sramek, JJ, Cutler, NR

“…OBJECTIVE: To review data generated by studies examining gender differences in the prevalence of depression, as well as in antidepressant pharmacokinetics,…”
Get full text

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial by Sramek, J J, Leibowitz, M T, Weinstein, S P, Rowe, E D, Mendel, C M, Levy, B, McMahon, F G, Mullican, W S, Toth, P D, Cutler, N R

“…Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an…”
Get full text

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin by CUTLER, N. R, VINCENT, J, JHEE, S. S, TENG, R, WARDLE, T, LUCAS, G, DOGOLO, L. C, SRAMEK, J. J

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder by BAMMERT ADAMS, J, PYKE, R. E, COSTA, J, CUTLER, N. R, SCHWEIZER, E, WILCOX, C. S, WISSELINK, P. G, GREINER, M, PIERCE, M. W, PANDE, A. C

“…This multicenter, double-blind, placebo-controlled, parallel-group, randomized study assessed the efficacy, safety, and tolerability of a novel CCK-B…”
Get full text

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder by KRAMER, M. S, CUTLER, N. R, BALLENGER, J. C, PATTERSON, W. M, MENDELS, J, CHENAULT, A, RAM SHRIVASTAVA, MATZURA-WOLFE, D, LINES, C, REINES, S

“…The functional role of cholecystokinin in the central nervous system is unknown. The tetra peptide CCK-4 was previously observed to induce panic attacks in a…”
Get full text

Ethnicity and antipsychotic response by Frackiewicz, E J, Sramek, J J, Herrera, J M, Kurtz, N M, Cutler, N R

“…To review the data generated by studies examining interethnic/racial differences in response to antipsychotics. A MEDLINE search (1966-1996) identified all…”
Get more information